Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

AMARIN CORP PLC\UK Operating Cash Flow

AMARIN CORP PLC\UK (AMRN) reported Operating Cash Flow of $12.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-29

  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $6.60M, a 60.23% decline year-over-year.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $6.39M.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $15.28M.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.70M.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for fiscal 2025 was $6.73M.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for fiscal 2024 was -$31.02M, a 550.87% decline from fiscal 2023.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for fiscal 2023 was $6.88M.
  • AMARIN CORP PLC\UK net cash provided by (used in) operating activities for fiscal 2022 was -$180.09M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30$6.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$12.99M
10-Q · filed 2026-07-29
$28.27M
derived: sum of 3 quarters · filed 2026-07-29
$15.57M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$6.39M
10-Q · filed 2026-04-29
$21.67M
derived: sum of 2 quarters · filed 2026-04-29
$8.97M
derived: sum of 3 quarters · filed 2026-04-29
$25.57M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$15.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$2.58M
derived: sum of 2 quarters · filed 2026-03-02
$19.19M
derived: sum of 3 quarters · filed 2026-07-29
$6.73M
10-K · filed 2026-03-02
2025-09-30-$12.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$3.91M
derived: sum of 2 quarters · filed 2026-07-29
-$8.55M
10-Q · filed 2025-10-29
-$21.86M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$16.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$4.15M
10-Q · filed 2026-07-29
-$9.16M
derived: sum of 3 quarters · filed 2026-07-29
-$11.52M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31-$12.46M
10-Q · filed 2026-04-29
-$25.77M
derived: sum of 2 quarters · filed 2026-04-29
-$28.13M
derived: sum of 3 quarters · filed 2026-04-29
-$30.88M
derived: sum of 4 quarters · filed 2026-04-29
2024-12-31-$13.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
-$15.67M
derived: sum of 2 quarters · filed 2026-03-02
-$18.42M
derived: sum of 3 quarters · filed 2026-03-02
-$31.02M
10-K · filed 2026-03-02
2024-09-30-$2.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
-$5.11M
derived: sum of 2 quarters · filed 2025-10-29
-$17.71M
10-Q · filed 2025-10-29
-$18.36M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30-$2.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
-$15.35M
10-Q · filed 2025-07-30
-$15.99M
derived: sum of 3 quarters · filed 2026-03-02
-$8.67M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31-$12.60M
10-Q · filed 2025-05-07
-$13.25M
derived: sum of 2 quarters · filed 2026-03-02
-$5.92M
derived: sum of 3 quarters · filed 2026-03-02
$1.29M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31-$645.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$6.68M
derived: sum of 2 quarters · filed 2026-03-02
$13.89M
derived: sum of 3 quarters · filed 2026-03-02
$6.88M
10-K · filed 2026-03-02
2023-09-30$7.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
$14.53M
derived: sum of 2 quarters · filed 2024-10-30
$7.53M
10-Q · filed 2024-10-30
$9.08M
derived: sum of 4 quarters · filed 2025-03-12
2023-06-30$7.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31
$196.00K
10-Q · filed 2024-07-31
$1.75M
derived: sum of 3 quarters · filed 2025-03-12
-$16.46M
derived: sum of 4 quarters · filed 2025-03-12
2023-03-31-$7.01M
10-Q · filed 2024-05-01
-$5.46M
derived: sum of 2 quarters · filed 2025-03-12
-$23.67M
derived: sum of 3 quarters · filed 2025-03-12
-$88.25M
derived: sum of 4 quarters · filed 2025-03-12
2022-12-31$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12
-$16.66M
derived: sum of 2 quarters · filed 2025-03-12
-$81.25M
derived: sum of 3 quarters · filed 2025-03-12
-$180.09M
10-K · filed 2025-03-12
2022-09-30-$18.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
-$82.80M
derived: sum of 2 quarters · filed 2023-11-01
-$181.64M
10-Q · filed 2023-11-01
-$209.88M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30-$64.58M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
-$163.43M
10-Q · filed 2023-08-02
-$191.67M
derived: sum of 3 quarters · filed 2024-02-29
-$196.21M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31-$98.85M
10-Q · filed 2023-05-03
-$127.09M
derived: sum of 2 quarters · filed 2024-02-29
-$131.63M
derived: sum of 3 quarters · filed 2024-02-29
-$146.68M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31-$28.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
-$32.78M
derived: sum of 2 quarters · filed 2024-02-29
-$47.83M
derived: sum of 3 quarters · filed 2024-02-29
-$66.54M
10-K · filed 2024-02-29
2021-09-30-$4.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27
-$19.59M
derived: sum of 2 quarters · filed 2022-10-27
-$38.30M
10-Q · filed 2022-10-27
-$76.62M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30-$15.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
-$33.76M
10-Q · filed 2022-08-03
-$72.08M
derived: sum of 3 quarters · filed 2023-03-01
-$61.23M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31-$18.70M
10-Q · filed 2022-05-04
-$57.03M
derived: sum of 2 quarters · filed 2023-03-01
-$46.17M
derived: sum of 3 quarters · filed 2023-03-01
-$44.59M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31-$38.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
-$27.47M
derived: sum of 2 quarters · filed 2023-03-01
-$25.88M
derived: sum of 3 quarters · filed 2023-03-01
-$21.75M
10-K · filed 2023-03-01
2020-09-30$10.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$12.44M
derived: sum of 2 quarters · filed 2021-11-03
$16.58M
10-Q · filed 2021-11-03
$7.64M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$1.59M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$5.72M
10-Q · filed 2021-08-05
-$3.21M
derived: sum of 3 quarters · filed 2022-03-01
$18.54M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$4.14M
10-Q · filed 2021-04-29
-$4.80M
derived: sum of 2 quarters · filed 2022-03-01
$16.95M
derived: sum of 3 quarters · filed 2022-03-01
$32.86M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$8.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$12.81M
derived: sum of 2 quarters · filed 2022-03-01
$28.72M
derived: sum of 3 quarters · filed 2022-03-01
-$9.37M
10-K · filed 2022-03-01
2019-09-30$21.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$37.66M
derived: sum of 2 quarters · filed 2020-11-05
-$430.00K
10-Q · filed 2020-11-05
-$32.73M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$15.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$22.18M
10-Q · filed 2020-08-04
-$54.48M
derived: sum of 3 quarters · filed 2021-02-25
-$82.64M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$38.09M
10-Q · filed 2020-04-30
-$70.39M
derived: sum of 2 quarters · filed 2021-02-25
-$98.55M
derived: sum of 3 quarters · filed 2021-02-25
-$122.99M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31-$32.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
-$60.46M
derived: sum of 2 quarters · filed 2021-02-25
-$84.90M
derived: sum of 3 quarters · filed 2021-02-25
-$94.70M
10-K · filed 2021-02-25
2018-09-30-$28.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
-$52.59M
derived: sum of 2 quarters · filed 2019-11-05
-$62.40M
10-Q · filed 2019-11-05
-$64.54M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30-$24.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
-$34.24M
10-Q · filed 2019-07-31
-$36.38M
derived: sum of 3 quarters · filed 2020-02-25
-$42.66M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31-$9.80M
10-Q · filed 2019-05-01
-$11.95M
derived: sum of 2 quarters · filed 2020-02-25
-$18.22M
derived: sum of 3 quarters · filed 2020-02-25
2017-12-31-$2.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
-$8.42M
derived: sum of 2 quarters · filed 2020-02-25
-$32.84M
10-K · filed 2020-02-25
2017-09-30-$6.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
-$30.70M
10-Q · filed 2018-11-01
2017-06-30-$24.42M
10-Q · filed 2018-08-01
2016-12-31-$71.81M
10-K · filed 2019-02-27
2013-12-31-$33.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
-$77.92M
derived: sum of 2 quarters · filed 2014-02-27
-$130.70M
derived: sum of 3 quarters · filed 2014-02-27
-$190.34M
10-K · filed 2014-02-27
2013-09-30-$44.84M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
-$97.62M
derived: sum of 2 quarters · filed 2013-11-07
-$157.25M
10-Q · filed 2013-11-07
-$201.02M
derived: sum of 4 quarters · filed 2014-02-27
2013-06-30-$52.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08
-$112.42M
10-Q · filed 2013-08-08
-$156.18M
derived: sum of 3 quarters · filed 2014-02-27
-$195.60M
derived: sum of 4 quarters · filed 2014-02-27
2013-03-31-$59.63M
10-Q · filed 2013-05-09
-$103.40M
derived: sum of 2 quarters · filed 2014-02-27
-$142.82M
derived: sum of 3 quarters · filed 2014-02-27
-$164.20M
derived: sum of 4 quarters · filed 2014-02-27
2012-12-31-$43.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
-$83.18M
derived: sum of 2 quarters · filed 2014-02-27
-$104.57M
derived: sum of 3 quarters · filed 2014-02-27
-$122.30M
10-K · filed 2014-02-27
2012-09-30-$39.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
-$60.80M
derived: sum of 2 quarters · filed 2013-11-07
-$78.54M
10-Q · filed 2013-11-07
-$90.11M
derived: sum of 4 quarters · filed 2014-02-27
2012-06-30-$21.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08
-$39.12M
10-Q · filed 2013-08-08
-$50.70M
derived: sum of 3 quarters · filed 2014-02-27
-$58.98M
derived: sum of 4 quarters · filed 2014-02-27
2012-03-31-$17.74M
10-Q · filed 2013-05-09
-$29.31M
derived: sum of 2 quarters · filed 2014-02-27
-$37.59M
derived: sum of 3 quarters · filed 2014-02-27
-$48.37M
derived: sum of 4 quarters · filed 2014-02-27
2011-12-31-$11.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
-$19.85M
derived: sum of 2 quarters · filed 2014-02-27
-$30.63M
derived: sum of 3 quarters · filed 2014-02-27
-$39.44M
10-K · filed 2014-02-27
2011-09-30-$8.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08
-$19.05M
derived: sum of 2 quarters · filed 2012-11-08
-$27.86M
10-Q · filed 2012-11-08
-$37.40M
derived: sum of 4 quarters · filed 2013-02-28
2011-06-30-$10.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08
-$19.59M
10-Q · filed 2012-08-08
-$29.12M
derived: sum of 3 quarters · filed 2013-02-28
-$37.48M
derived: sum of 4 quarters · filed 2013-02-28
2011-03-31-$8.81M
10-Q · filed 2012-05-08
-$18.34M
derived: sum of 2 quarters · filed 2013-02-28
-$26.70M
derived: sum of 3 quarters · filed 2013-02-28
2010-12-31-$9.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28
-$17.89M
derived: sum of 2 quarters · filed 2013-02-28
-$33.87M
10-K · filed 2013-02-28
2010-09-30-$8.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08
-$24.34M
10-Q · filed 2011-11-08
2010-06-30-$15.98M
10-Q · filed 2011-08-09
2009-12-31-$28.41M
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B